OEP Pharma helps North American companies advance pharmaceutical innovation and reach new markets.
We are the US headquarters of OEP Group, a full-service, TWSE-listed company founded in Taiwan in 1982. OEP brings nearly 40 years of industry experience, sales and manufacturing capacity, regulatory expertise, and relationships to partners seeking to expand their product portfolios and global reach.
Blending the financial stability and corporate oversight of a publicly traded company with the entrepreneurial agility of a founder-led enterprise, we offer a seamless, tailored approach to all stages of product development and delivery.
OEP Group was founded in 1982 by CEO and Chairman Peter Tsai, who began his career as a top salesman for Pfizer’s Upjohn in Taiwan, helping it become the no. 2 pharmaceutical company in the country. He launched OEP to have an even greater impact as the regional distributor of choice for partners such as Sanofi’s Rhône-Poulenc and Pierre Fabre, among many others.
At a time when the region was just emerging on the radar of foreign companies, Peter helped to open the Taiwan, and later, ASEAN markets. After successfully establishing regional licensing and distribution networks in the 1980s and 90s, OEP began diversifying its global reach, product portfolio, and capabilities. Today, with two state-of-the-art facilities, and plans to expand its commercial networks to Australia and New Zealand, OEP Pharma is poised to help advance cutting-edge specialty products while accessing new markets.
Surrounded by a multi-generational family of doctors, Peter’s company vision has always been driven by what he sees around him: real patient needs. With Tsai family members treating patients in a range of specialties, including oncology, neurology, and cardiology, OEP has a finger on the pulse of arising needs in diverse fields; with longstanding licensing and sales experience and extensive sales forces on the ground, OEP listens carefully to what local consumers want and need. The result: an integrated vision for health and wellness that includes treatments from birth to end-of-life care, from infant formula and beauty products to anti-diabetes and cancer medication.
See our parent company’s Corporate Milestones.
Surrounded by a multi-generational family of doctors, Peter’s company vision has always been driven by what he sees around him: real patient needs. With Tsai family members treating patients in a range of specialties, including oncology, neurology, and cardiology, OEP has a finger on the pulse of arising needs in diverse fields; with longstanding licensing and sales experience and extensive sales forces on the ground, OEP listens carefully to what local consumers want and need.
The result: an integrated vision for health and wellness that includes treatments from birth to end-of-life care, from infant formula and beauty products to anti-diabetes and cancer medication.
See our parent company’s Corporate Milestones.
We are committed to bringing patients innovative, high-quality products that can enhance their health at a price they can afford. Already a partner of choice for product launches in Asia, OEP Pharma aims to become the collaborator of choice for North American pharmaceutical specialists and companies seeking to develop new products and reach new markets.
We leverage all of our corporate resources – investment capacity, local sales forces in over 10 countries, licensing and regulatory expertise, best-in-class, FDA-certified manufacturing plants, and growing ANDA and 505(b)(2) portfolios – to help partners successfully create, launch, and/or distribute products.
We do so with integrity and a focus on innovation and access.
We believe in the integrity of our people, processes, and products: we deliver what we say we will, when we say we will, and act with trustworthiness and an attention to ethics and transparency.
And just as healthcare is most effective when doctors take into account the whole individual, we encourage an integrated approach to what we do, whether that means being involved with partners from product conception to distribution, investing in a whole-life health product portfolio (from birth onwards), or promoting the work-life balance of our employees so they can perform at their peak.
We are an intellectually curious company, always seeking to learn, grow, and innovate. US subsidiary OEP Innovations represents the latest in our commitment to chart new frontiers in the pharmaceutical landscape, from building specialty product niches, and new ways to market and distribute products, to tapping new regions and creating new types of partnerships.
We got our start as a distribution company, devoted to opening new markets for leading European pharmaceutical companies such as Pierre Fabre, Upjohn (Pfizer), Rhône-Poulenc (Sanofi), and Elan (Perrigo). At the same time, we helped an emerging Taiwanese middle class gain access to high-quality medicines. Enhancing access, for both our partners and patients, remains a core purpose of our business.
These key values enable us to achieve collaborative synergy with our partners.
© 2020 OEP Pharma. All right reserved.
